Form 4: Lifecore Biomedical Director Matthew Korenberg Reports Acquisition of Restricted Stock Units
SEC Form 4 Filing
Director Matthew E. Korenberg reports acquisition of 24,554 restricted stock units in Lifecore Biomedical, Inc.
Summary
- On August 19, 2024, Matthew E. Korenberg, a director of Lifecore Biomedical, Inc., acquired 24,554 restricted stock units.
- These restricted stock units convert into common stock on a 1-for-1 basis.
- The units vest on the earlier of July 8, 2025, or the date of the company's annual meeting in 2025, provided it's at least 50 weeks from July 8, 2024.
- Following the transaction, Korenberg directly owns 24,554 shares of common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing the acquisition of restricted stock units by a company director. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to insider transactions and is a standard practice for publicly traded companies. It provides transparency into the holdings and transactions of company insiders.
Stakeholder Impact
- The acquisition of restricted stock units by a director may signal confidence in the company's future performance to shareholders.
Key Dates
| Date | Description |
|---|---|
| 08/19/2024 | Date of transaction: Matthew E. Korenberg acquired 24,554 restricted stock units. |
| 07/08/2025 | Earliest vesting date for the restricted stock units. |
| 08/21/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.